Click on any article title below to view reprint (requires Adobe Acrobat Reader)

---

Prod'homme T, Zamvil SS.

Bench to Bedside: Tempering antigen-presenting cells in multiple sclerosis.

Nature Medicine. 2008. 14:614-615.

---

Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS.

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

Nature Medicine. 2007. 13:935-943.

---

Prod'homme T, Weber MS, Zamvil SS.

T effectors outfox T regulators in autoimmunity.

Nature Medicine. 2007. 13:411-413.

---

Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS.

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

Journal of Clinical Investigation. 2006. 116:1037-1044.

---

Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L.

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.

Journal of Experimental Medicine. 2006. 203:401-412.

---

Zamvil SS, Steinman L.

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

Annals of Neurology. 2006. 60:12-21.

---

Greenwood J, Steinman L, Zamvil SS.

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Nature Reviews Immunology. 2006. 6:358-370.

---

Prod'homme T, Weber MS, Steinman L, Zamvil SS.

A neuropeptide in immune-mediated inflammation, Y?

Trends in Immunology. 2006. 27:164-178.

---

Steinman L, Zamvil SS.

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

Trends in Immunology. 2005. 26:565-571.

---

Zamvil SS, Steinman L.

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.

Neuron. 2003. 38:685-688.

---

Zamvil SS, Steinman L.

Transcriptional analysis of targets in multiple sclerosis.

Nature Reviews Immunology. 2003. 3:483-492.

---

Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS.

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Nature. 2002. 420:78-84.

---

Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS.

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.

Journal of Immunology. 2002. 169:6720-6732.

---

Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, Fontana A, Bikoff EK, Zamvil SS.

Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity.

Journal of Clinical Investigation. 2001. 108:1133-1139.

---

Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS.

Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).

Genes and Immunity. 2002. 3:34-37.

---